Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors

Journal of Medicinal Chemistry

Volumn 58, Issue 17, 2015, Pages 6928-6937

  Borišek, Jure ^a   Vizovišek, Matej ^b   Sosnowski, Piotr ^b   Turk, Boris ^b,c   Turk, Dušan ^b,c,d   Mohar, Barbara ^a   Novič, Marjana ^a  

^a NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

^b JO EF STEFAN INSTITUTE   (Slovenia)

^c Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins   (Slovenia)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

4 BROMOISATOIC ANHYDRIDE; 4 CHLOROISATOIC ANHYDRIDE; 7 CHLORO 2 TRIFLUOROMETHYL 4H 3,1 BENZOXAZIN 4 ONE; CATHEPSIN K; CATHEPSIN K INHIBITOR; CATHEPSIN L; CATHEPSIN S; CYSTEINE; HOMOCYCLOLEUCINE N CARBOXYLIC ACID ANHYDRIDE; HOMOCYCLOLEUCYL GLYCINONITRILE; N (2 AMINO 4 BROMOBENZOYL)HOMOCYCLOLEUCYL GLYCINONITRILE; N (2 AMINO 4 CHLOROBENZOYL)HOMOCYCLOLEUCYL GLYCINONITRILE; N (2 TRIFLUOROACETAMIDO 4 CHLOROBENZOYL)HOMOCYCLOLEUCYL GLYCINONITRILE; N (3 FLUORO 4 AMINOBENZOYL)HOMOCYCLOLEUCYL GLYCINONITRILE; N (3 FLUORO 4 NITROBENZOYL)HOMOCYCLOLEUCYL GLYCINONITRILE; N (4 AMINO 3 FLUOROBENZOYL)PIPERIDINE; N (4 AMINO 3 FLUOROBENZOYLOXYCARBONYL)PIPERIDINE; N ETHOXYCARBONYL HOMOCYCLOLEUCINE; N TRIFLUOROACETYL 4 CHLOROANTHRANILIC ACID; N [3 FLUORO 4 (PIPERIDINOCARBOXAMIDO)BENZOYL] HOMOCYCLOLEUCYL GLYCINONITRILE; N [4 (2 ETHYL BUTYRAMIDO) 3 FLUOROBENZOYL]HOMOCYCLOLEUCYL GLYCINONITRILE; NITRILE; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; CYCLOLEUCINE; DIPEPTIDE; GLYCINE; PROTEIN BINDING;

ARTICLE; BIOCHEMICAL ANALYSIS; BIOLOGICAL ACTIVITY; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; COVALENT BOND; DRUG DEVELOPMENT; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; LIGAND BINDING; MOLECULAR DOCKING; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VIRTUAL COMBINATORIAL CHEMISTRY; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; KINETICS; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

BENZOATES; CATHEPSIN K; CRYSTALLOGRAPHY, X-RAY; CYCLOLEUCINE; DIPEPTIDES; GLYCINE; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; NITRILES; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84941584558     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00746     Document Type: Article

References (64)

1. Fonovic, M.; Turk, B. Cysteine cathepsins and extracellular matrix degradation Biochim. Biophys. Acta, Gen. Subj. 2014, 1840, 2560-2570 10.1016/j.bbagen.2014.03.017
2. Novinec, M.; Lenarcic, B. Cathepsin K: a unique collagenolytic cysteine peptidase Biol. Chem. 2013, 394, 1163-1179 10.1515/hsz-2013-0134
3. Deaton, D. M.; Kumar, S. 6. Cathepsin K inhibitors: their potential as anti-osteoporosis agents Prog. Med. Chem. 2004, 42, 245-375 10.1016/S0079-6468(04)42006-2
4. Katunuma, N. Structure-based development of specific inhibitors for individual cathepsins and their medical applications Proc. Jpn. Acad., Ser. B 2011, 87, 29-39 10.2183/pjab.87.29
5. Nomura, T.; Katunuma, N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells J. Med. Invest. 2005, 52, 1-9 10.2152/jmi.52.1
6. Turk, V.; Turk, B.; Turk, D. Lysosomal cysteine proteases: facts and opportunities EMBO J. 2001, 20, 4629-4633 10.1093/emboj/20.17.4629
7. Turk, V.; Stoka, V.; Vasiljeva, O.; Renko, M.; Sun, T.; Turk, B.; Turk, D. Cysteine cathepsins: from structure, function and regulation to new frontiers Biochim. Biophys. Acta, Proteins Proteomics 2012, 1824, 68-88 10.1016/j.bbapap.2011.10.002
8. Aguda, A. H.; Panwar, P.; Du, X.; Nguyen, N. T.; Brayer, G. D.; Brömme, D. Structural basis of collagen fiber degradation by cathepsin K Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 17474-17479 10.1073/pnas.1414126111
9. Hua, Y.; Nair, S. Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications Biochim. Biophys. Acta, Mol. Basis Dis. 2015, 1852, 195-208 10.1016/j.bbadis.2014.04.032
10. Nagase, S.; Ohyama, M.; Hashimoto, Y.; Small, M.; Sharpe, J.; Manako, J.; Kuwayama, T.; Deacon, S. Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women J. Bone Miner. Metab. 2015, 33, 93-100 10.1007/s00774-013-0558-2
11. Cheng, X. W.; Shi, G. P.; Kuzuya, M.; Sasaki, T.; Okumura, K.; Murohara, T. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication Circulation 2012, 125, 1551-1562 10.1161/CIRCULATIONAHA.111.066712
12. Brömme, D.; Lecaille, F. Cathepsin K inhibitors for osteoporosis and potential off-target effects Expert Opin. Invest. Drugs 2009, 18, 585-600 10.1517/13543780902832661
13. Vassalle, C.; Iervasi, G. Cathepsin K-A classical bone biomarker in cardiovascular disease: The heart is not alone anymore Atherosclerosis 2013, 228, 36-37 10.1016/j.atherosclerosis.2013.01.042
14. Hua, Y.; Zhang, Y.; Dolence, J.; Shi, G. P.; Ren, J.; Nair, S. Cathepsin K knockout mitigates high-fat diet-induced cardiac hypertrophy and contractile dysfunction Diabetes 2013, 62, 498-509 10.2337/db12-0350
15. Frizler, M.; Stirnberg, M.; Sisay, M. T.; Gütschow, M. Development of Nitrile-Based Peptidic Inhibitors of Cysteine Cathepsins Curr. Top. Med. Chem. 2010, 10, 294-322 10.2174/156802610790725452
16. Wijkmans, J.; Gossen, J. Inhibitors of cathepsin K: a patent review (2004-2010) Expert Opin. Ther. Pat. 2011, 21, 1611-1629 10.1517/13543776.2011.616283
17. Chapurlat, R. D. Treatment of postmenopausal osteoporosis with odanacatib Expert Opin. Pharmacother. 2014, 15, 559-564 10.1517/14656566.2014.881470
18. Engelke, K.; Nagase, S.; Fuerst, T.; Small, M.; Kuwayama, T.; Deacon, S.; Eastell, R.; Genant, H. K. The Effect of the Cathepsin K Inhibitor ONO-5334 on Trabecular and Cortical Bone in Postmenopausal Osteoporosis: The OCEAN Study J. Bone Miner. Res. 2014, 29, 629-638 10.1002/jbmr.2080
19. Duong, L. T.; Wesolowski, G. A.; Leung, P.; Oballa, R.; Pickarski, M. Efficacy of a Cathepsin K Inhibitor in a Preclinical Model for Prevention and Treatment of Breast Cancer Bone Metastasis Mol. Cancer Ther. 2014, 13, 2898-2909 10.1158/1535-7163.MCT-14-0253
20. Nakamura, T.; Shiraki, M.; Fukunaga, M.; Tomomitsu, T.; Santora, A. C.; Tsai, R.; Fujimoto, G.; Nakagomi, M.; Tsubouchi, H.; Rosenberg, E.; Uchida, S. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis-a double-blind, randomized, dose-finding study Osteoporosis Int. 2014, 25, 367-376 10.1007/s00198-013-2398-2
21. Brixen, K.; Chapurlat, R.; Cheung, A. M.; Keaveny, T. M.; Fuerst, T.; Engelke, K.; Recker, R.; Dardzinski, B.; Verbruggen, N.; Ather, S.; Rosenberg, E.; de Papp, A. E. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial J. Clin. Endocrinol. Metab. 2013, 98, 571-580 10.1210/jc.2012-2972
22. Stoch, S. A.; Zajic, S.; Stone, J. A.; Miller, D. L.; van Bortel, L.; Lasseter, K. C.; Pramanik, B.; Cilissen, C.; Liu, Q.; Liu, L.; Scott, B. B.; Panebianco, D.; Ding, Y.; Gottesdiener, K.; Wagner, J. A. Odanacatib, a Selective Cathepsin K inhibitor to Treat Osteoporosis: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics-Results from Single Oral Dose Studies in Healthy Volunteers Br. J. Clin. Pharmacol. 2013, 75, 1240-1254 10.1111/j.1365-2125.2012.04471.x
23. Nagase, S.; Hashimoto, Y.; Small, M.; Ohyama, M.; Kuwayama, T.; Deacon, S. Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women Br. J. Clin. Pharmacol. 2012, 74, 959-970 10.1111/j.1365-2125.2012.04307.x
24. Ng, K. W. Potential role of odanacatib in the treatment of osteoporosis Clin. Interventions Aging 2012, 7, 235-247 10.2147/CIA.S26729
25. Ochi, Y.; Yamada, H.; Mori, H.; Nakanishi, Y.; Nishikawa, S.; Kayasuga, R.; Kawada, N.; Kunishige, A.; Hashimoto, Y.; Tanaka, M.; Sugitani, M.; Kawabata, K. Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism Bone 2011, 49, 1351-1356 10.1016/j.bone.2011.09.041
26. Rünger, T. M.; Adami, S.; Benhamou, C. L.; Czerwiński, E.; Farrerons, J.; Kendler, D. L.; Mindeholm, L.; Realdi, G.; Roux, C.; Smith, V. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib J. Am. Acad. Dermatol. 2012, 66, e89-e96 10.1016/j.jaad.2010.11.033
27. Falgueyret, J. P.; Desmarais, S.; Oballa, R.; Black, W. C.; Cromlish, W.; Khougaz, K.; Lamontagne, S.; Massé, F.; Riendeau, D.; Toulmond, S.; Percival, M. D. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity J. Med. Chem. 2005, 48, 7535-7543 10.1021/jm0504961
28. McGrath, M. E.; Klaus, J. L.; Barnes, M. G.; Brömme, D. Crystal structure of human cathepsin K complexed with a potent inhibitor Nat. Struct. Biol. 1997, 4, 105-109 10.1038/nsb0297-105
29. Turk, D.; Guncar, G.; Podobnik, M.; Turk, B. Revised definition of substrate binding sites of papain-like cysteine proteases Biol. Chem. 1998, 379, 137-147 10.1515/bchm.1998.379.2.137
30. Minovski, N.; Perdih, A.; Solmajer, T. Combinatorially-generated library of 6-fluoroquinolone analogs as potential novel antitubercular agents: a chemometric and molecular modeling assessment J. Mol. Model. 2012, 18, 1735-1753 10.1007/s00894-011-1179-0
31. Minovski, N.; Perdih, A.; Novic, M.; Solmajer, T. Cluster-based molecular docking study for in silico identification of novel 6-fluoroquinolones as potential inhibitors against mycobacterium tuberculosis J. Comput. Chem. 2013, 34, 790-801 10.1002/jcc.23205
32. Borišek, J.; Drgan, V.; Minovski, N.; Novič, M. Mechanistic interpretation of artificial neural network-based QSAR model for prediction of cathepsin K inhibition potency J. Chemom. 2014, 28, 272-281 10.1002/cem.2617
33. Enamine fragment database. URL: http://www.enamine.net/index.php?option=com
34. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A rule of three for fragment-based lead discovery? Drug Discovery Today 2003, 8, 876-877 10.1016/S1359-6446(03)02831-9
35. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615-2623 10.1021/jm020017n
36. Dossetter, A. G.; Beeley, H.; Bowyer, J.; Cook, C. R.; Crawford, J. J.; Finlayson, J. E.; Heron, N. M.; Heyes, C.; Highton, A. J.; Hudson, J. A.; Jestel, A.; Kenny, P. W.; Krapp, S.; Martin, S.; MacFaul, P. A.; McGuire, T. M.; Gutierrez, P. M.; Morley, A. D.; Morris, J. J.; Page, K. M.; Ribeiro, L. R.; Sawney, H.; Steinbacher, S.; Smith, C.; Vickers, M. (1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole '2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis J. Med. Chem. 2012, 55, 6363-6374 10.1021/jm3007257
37. Palmer, J. T.; Bryant, C.; Wang, D. X.; Davis, D. E.; Setti, E. L.; Rydzewski, R. M.; Venkatraman, S.; Tian, Z. Q.; Burrill, L. C.; Mendonca, R. V.; Springman, E.; McCarter, J.; Chung, T.; Cheung, H.; Janc, J. W.; McGrath, M.; Somoza, J. R.; Enriquez, P.; Yu, Z. W.; Strickley, R. M.; Liu, L.; Venuti, M. C.; Percival, M. D.; Falgueyret, J. P.; Prasit, P.; Oballa, R.; Riendeau, D.; Young, R. N.; Wesolowski, G.; Rodan, S. B.; Johnson, C.; Kimmel, D. B.; Rodan, G. Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K J. Med. Chem. 2005, 48, 7520-7534 10.1021/jm058198r
38. Frizler, M.; Lohr, F.; Furtmann, N.; Kläs, J.; Gütschow, M. Structural Optimization of Azadipeptide Nitriles Strongly Increases Association Rates and Allows the Development of Selective Cathepsin Inhibitors J. Med. Chem. 2011, 54, 396-400 10.1021/jm101272p
39. Frizler, M.; Lohr, F.; Lülsdorff, M.; Gütschow, M. Facing the gem-Dialkyl Effect in Enzyme Inhibitor Design: Preparation of Homocycloleucine-Based Azadipeptide Nitriles Chem.-Eur. J. 2011, 17, 11419-11423 10.1002/chem.201101350
40. Falgueyret, J. P.; Desmarais, S.; Oballa, R.; Black, W. C.; Cromlish, W.; Khougaz, K.; Lamontagne, S.; Massé, F.; Riendeau, D.; Toulmond, S.; Percival, M. D. Lysosomotropism of Basic Cathepsin K Inhibitors Contributes to Increased Cellular Potencies against Off-Target Cathepsins and Reduced Functional Selectivity J. Med. Chem. 2005, 48, 7535-43 10.1021/jm0504961
41. Schröder, J.; Klinger, A.; Oellien, F.; Marhöfer, R. J.; Duszenko, M.; Selzer, P. M. Docking-based virtual screening of covalently binding ligands: an orthogonal lead discovery approach J. Med. Chem. 2013, 56, 1478-1490 10.1021/jm3013932
42. Barrett, A. J.; Kembhavi, A. A.; Brown, M. A.; Kirschke, H.; Knight, C. G.; Tamai, M.; Hanada, K. L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogs as inhibitors of cysteine proteinases including cathepsins B, H and L Biochem. J. 1982, 201, 189-198 10.1042/bj2010189
43. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748 10.1006/jmbi.1996.0897
44. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD Proteins: Struct., Funct., Genet. 2003, 52, 609-623 10.1002/prot.10465
45. Nissink, J. W.; Murray, C.; Hartshorn, M.; Verdonk, M. L.; Cole, J. C.; Taylor, R. A new test set for validating predictions of protein-ligand interaction Proteins: Struct., Funct., Genet. 2002, 49, 457-471 10.1002/prot.10232
46. Kirchmair, J.; Markt, P.; Distinto, S.; Wolber, G.; Langer, T. Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection-What can we learn from earlier mistakes? J. Comput.-Aided Mol. Des. 2008, 22, 213-228 10.1007/s10822-007-9163-6
47. Carter, M. C.; Alber, D. G.; Baxter, R. C.; Bithell, S. K.; Budworth, J.; Chubb, A.; Cockerill, G. S.; Dowdell, V. C. L.; Henderson, E. A.; Keegan, S. J.; Kelsey, R. D.; Lockyer, M. J.; Stables, J. N.; Wilson, L. J.; Powell, K. L. 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus J. Med. Chem. 2006, 49, 2311-2319 10.1021/jm051185t
48. Bernhart, C.; Bouaboula, M.; Casellas, P.; Duclos, O.; Herbert, J. M.; Jegham, S.; Mccort, G. Antineoplastic derivatives, preparation thereof, and therapeutic use thereof. Patent WO2010004198 A2, 2010.
49. Olson, D. R.; Wheeler, W. J.; Wells, J. N. Rigid Analogs of Indomethacin J. Med. Chem. 1974, 17, 167-171 10.1021/jm00248a005
50. Mihelic, M.; Dobersek, A.; Guncar, G.; Turk, D. Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation J. Biol. Chem. 2008, 283, 14453-60 10.1074/jbc.M801283200
51. Brömme, D.; Nallaseth, F. S.; Turk, B. Production and activation of recombinant papain-like cysteine proteases Methods 2004, 32, 199-206 10.1016/S1046-2023(03)00212-3
52. Rozman-Pungercar, J.; Kopitar-Jerala, N.; Bogyo, M.; Turk, D.; Vasiljeva, O.; Stefe, I.; Vandenabeele, P.; Brömme, D.; Puizdar, V.; Fonović, M.; Trstenjak-Prebanda, M.; Dolenc, I.; Turk, V.; Turk, B. Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificity Cell Death Differ. 2003, 10, 881-8 10.1038/sj.cdd.4401247
53. Greco, W. R.; Hakala, M. T. Evaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors J. Biol. Chem. 1979, 254, 12104-9
54. Cherney, M. M.; Lecaille, F.; Kienitz, M.; Nallaseth, F. S.; Li, Z.; James, M. N.; Brömme, D. Structure-activity analysis of cathepsin K/chondroitin 4-sulfate interactions J. Biol. Chem. 2011, 286, 8988-98 10.1074/jbc.M110.126706
55. Kirschke, H.; Barrett, A. J.; Rawlings, N. D. Proteinases 1: lysosomal cysteine proteinases Protein Profile 1995, 2, 1581-643
56. Turk, B.; Colić, A.; Stoka, V.; Turk, V. Kinetics of inhibition of bovine cathepsin S by bovine stefin B FEBS Lett. 1994, 339, 155-159 10.1016/0014-5793(94)80405-2
57. Morrison, J. F. The slow-binding and slow, tight-binding inhibition of enzyme-catalysed reactions Trends Biochem. Sci. 1982, 7, 102-105 10.1016/0968-0004(82)90157-8
58. Invitrogen. Pichia Expression Kit. http://tools.thermofisher.com/content/sfs/manuals/pich
59. Mueller, U.; Darowski, N.; Fuchs, M. R.; Förster, R.; Hellmig, M.; Paithankar, K. S.; Pühringer, S.; Steffien, M.; Zocher, G.; Weiss, M. S. Facilities for macromolecular crystallography at the Helmholtz-Zentrum Berlin J. Synchrotron Radiat. 2012, 19, 442-449 10.1107/S0909049512006395
60. Krug, M.; Weiss, M. S.; Heinemann, U.; Mueller, U. XDSAPP: a graphical user interface for the convenient processing of diffraction data using XDS J. Appl. Crystallogr. 2012, 45, 568-572 10.1107/S0021889812011715
61. Mccoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674 10.1107/S0021889807021206
62. Murshudov, G. N.; Skubák, P.; Lebedev, A. A.; Pannu, N. S.; Steiner, R. A.; Nicholls, R. A.; Winn, M. D.; Long, F.; Vagin, A. A. REFMAC5 for the refinement of macromolecular crystal structures Acta Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67, 355-367 10.1107/S0907444911001314
63. Turk, D. MAIN software for density averaging, model building, structure refinement and validation Acta Crystallogr., Sect. D: Biol. Crystallogr. 2013, 69, 1342-1357 10.1107/S0907444913008408
64. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 486-501 10.1107/S0907444910007493